HUTCHMED (NASDAQ: HCM) is a global biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immuno-oncology treatments for patients in oncology and autoimmune diseases. Established in 2000 as Hutchison China MediTech, the company has evolved into an end-to-end drug developer, maintaining integrated research and development (R&D), manufacturing and commercial capabilities. Headquartered in Shanghai with operations across Asia, Europe and North America, HUTCHMED leverages a deep understanding of molecular oncology to advance novel candidates from early research through regulatory approval and market launch.
The company’s pipeline encompasses small molecules and biologics, including both internally developed and partnered assets. Key programs target solid tumors such as lung, gastric and breast cancer, as well as hematological malignancies. Several late-stage assets have entered pivotal trials or regulatory review in multiple jurisdictions. HUTCHMED’s portfolio also includes selective kinase inhibitors and monoclonal antibodies designed to improve patient outcomes through precision medicine approaches that address specific genetic and immunological drivers of disease.
HUTCHMED has established commercial operations in mainland China, where it markets and distributes oncology products in collaboration with local partners. In addition to its Shanghai manufacturing facility, the company operates state-of-the-art R&D centers in Beijing and Suzhou, as well as a U.S. office in New Jersey that supports global regulatory and clinical activities. HUTCHMED’s strategic footprint allows it to conduct multinational clinical trials and streamline the transition of late-stage assets into global markets.
Under the leadership of a seasoned executive team with extensive experience in biopharmaceutical development, HUTCHMED emphasizes scientific rigor, operational excellence and patient-centric innovation. The board and management team bring diverse backgrounds in drug discovery, clinical development and commercial strategy, guiding the company’s mission to deliver transformative therapies to patients worldwide. Through sustained investment in research capabilities and strategic partnerships, HUTCHMED aims to maintain its position at the forefront of oncology and immunology therapeutics.
AI Generated. May Contain Errors.
